Codon-Optimized Soybean Seeds for hEGF Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing human epidermal growth factor (hEGF) are not efficient enough to meet therapeutic requirements for conditions like necrotizing enterocolitis in premature infants, and there is a need for a sustainable and scalable production method.
Innovation Solution
The production of hEGF in soybean seeds using transgenic soybeans engineered to express a codon-optimized gene with an ER signal tag, achieving high accumulation levels comparable to commercially available hEGF, and utilizing soybean-derived hEGF in soymilk as a delivery platform.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to produce hEGF, then production capacity is limited, but meeting therapeutic requirements becomes difficult
Solution Approach 1:
The patent uses soybean seeds as a biological intermediary system (biofactory) to produce hEGF. The transgenic soybean plants express the hEGF protein through their natural biological processes, acting as living factories that convert genetic information into therapeutic protein product, thereby achieving scalable production without conventional cell culture limitations
Solution Approach 2:
The patent employs codon optimization to change the nucleotide sequence parameters of the hEGF gene to match soybean's preferred codon usage patterns. This parameter change in the genetic code enhances translation efficiency and protein expression levels in the soybean system, directly improving production capacity
2Productivity
If transgenic soybean system is used, then production scalability is improved, but gene transformation complexity increases
Solution Approach 1:
The patent performs preliminary codon optimization of the hEGF gene sequence before transformation into soybean. By pre-adapting the genetic code to soybean's preferences and adding appropriate regulatory elements, the transformation process becomes more efficient and predictable, reducing the complexity of subsequent expression optimization
Solution Approach 2:
The patent divides the hEGF production system into distinct functional segments: the codon-optimized coding sequence, the promoter region for tissue-specific expression, and the regulatory elements. This modular segmentation allows independent optimization of each component and simplifies the overall transformation and expression system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves biologically relevant and bioactive hEGF production in soybean seeds, exceeding therapeutic requirements and demonstrating the feasibility of soybeans as a biofactory for therapeutic agents, with potential applications in intestinal healing and other uses.
Implementation Method 1
transgenic soybeans engineered to express a codon-optimized gene
Implementation Method 2
codon-optimized gene with an ER signal tag
Data Source
AI summary
Methods and compositions for producing epidermal growth factor (EGF) in soybean seeds featuring the use of transgenic soybean seeds expressing a seed-specific codon optimized gene encoding of the hEGF protein. Using these methods, the production of hEGF is sufficient and the activity of the EGF protein is comparable to commercially available EGF. The present invention shows the feasibility of using soybean seeds as a biofactory to produce therapeutic agents for a delivery platform, e.g., in a soymilk delivery platform.